Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Richard M. Stone, M.D.

Co-Author

This page shows the publications co-authored by Richard Stone and Robert Hasserjian.
Connection Strength

0.619
  1. Reproducibility and prognostic significance of morphologic dysplasia in de novo acute myeloid leukemia. Mod Pathol. 2015 Jul; 28(7):965-76.
    View in: PubMed
    Score: 0.164
  2. De novo acute myeloid leukemia with 20-29% blasts is less aggressive than acute myeloid leukemia with =30% blasts in older adults: a Bone Marrow Pathology Group study. Am J Hematol. 2014 Nov; 89(11):E193-9.
    View in: PubMed
    Score: 0.156
  3. A novel differentiation response with combination IDH inhibitor and intensive induction therapy for AML. Blood Adv. 2021 Apr 27; 5(8):2279-2283.
    View in: PubMed
    Score: 0.062
  4. High NPM1 mutant allele burden at diagnosis correlates with minimal residual disease at first remission in de novo acute myeloid leukemia. Am J Hematol. 2019 08; 94(8):921-928.
    View in: PubMed
    Score: 0.055
  5. Clinical, immunophenotypic, and genomic findings of acute undifferentiated leukemia and comparison to acute myeloid leukemia with minimal differentiation: a study from the bone marrow pathology group. Mod Pathol. 2019 09; 32(9):1373-1385.
    View in: PubMed
    Score: 0.054
  6. High NPM1-mutant allele burden at diagnosis predicts unfavorable outcomes in de novo AML. Blood. 2018 06 21; 131(25):2816-2825.
    View in: PubMed
    Score: 0.050
  7. Effect of treatment with a JAK2-selective inhibitor, fedratinib, on bone marrow fibrosis in patients with myelofibrosis. J Transl Med. 2015 Sep 10; 13:294.
    View in: PubMed
    Score: 0.042
  8. A phase II study of the oral VEGF receptor tyrosine kinase inhibitor vatalanib (PTK787/ZK222584) in myelodysplastic syndrome: Cancer and Leukemia Group B study 10105 (Alliance). Invest New Drugs. 2013 Oct; 31(5):1311-20.
    View in: PubMed
    Score: 0.036
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.